← Back to Screener
Lyra Therapeutics, Inc. Common Stock (LYRA)
Price$0.70
Growth ScoreF
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-90.63%
Price vs S&P 500 (4W)-9.06%
VGM Score8.88
Market Capitalization$1.24M
All Metrics
Book Value / Share (Quarterly)$1.00
P/TBV (Annual)1.87x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-33.61%
Cash Flow / Share (Quarterly)$-16.32
Price vs S&P 500 (YTD)-88.66%
Net Profit Margin (TTM)-7266.08%
EPS (TTM)$-19.31
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-19.31
Revenue Growth (5Y)4.35%
EPS (Annual)$-18.62
ROI (Annual)-805.89%
Net Profit Margin (5Y Avg)-7289.66%
Cash / Share (Quarterly)$8.95
Revenue Growth QoQ (YoY)-96.65%
ROA (Last FY)-80.09%
Revenue Growth TTM (YoY)-74.05%
EBITD / Share (TTM)$-19.69
ROE (5Y Avg)-220.19%
Operating Margin (TTM)-7794.47%
Cash Flow / Share (Annual)$-16.32
P/B Ratio0.77x
P/B Ratio (Quarterly)8.98x
Net Income / Employee (Annual)$-1,071,100
EV / Revenue (TTM)-36.81x
ROA (TTM)-61.30%
EPS Incl Extra (Annual)$-18.62
Current Ratio (Annual)1.71x
Quick Ratio (Quarterly)1.67x
3-Month Avg Trading Volume0.05M
52-Week Price Return-96.54%
Revenue / Employee (TTM)$14,700
Tangible BV / Share (Quarterly)$1.70
P/S Ratio (Annual)3.12x
Asset Turnover (Annual)0.01x
52-Week High$37.50
Operating Margin (5Y Avg)-7513.04%
EPS Excl Extra (Annual)$-18.62
CapEx CAGR (5Y)-42.08%
26-Week Price Return-77.05%
Quick Ratio (Annual)1.67x
13-Week Price Return-41.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.71x
Enterprise Value$-14.65M
Revenue / Share Growth (5Y)63.77%
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$14,700
Pretax Margin (Annual)-7263.32%
Cash / Share (Annual)$8.95
3-Month Return Std Dev170.25%
Net Income / Employee (TTM)$-1,071,100
ROE (Last FY)-805.89%
EPS Basic Excl Extra (Annual)$-18.62
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-19.31
ROI (TTM)-411.98%
P/S Ratio (TTM)3.12x
Pretax Margin (5Y Avg)-7287.69%
Revenue / Share (Annual)$0.26
Tangible BV / Share (Annual)$2.54
Price vs S&P 500 (52W)-124.70%
Year-to-Date Return-77.27%
5-Day Price Return-10.26%
EPS Normalized (Annual)$-18.62
ROA (5Y Avg)-78.88%
Net Profit Margin (Annual)-7266.08%
Month-to-Date Return-5.41%
Cash Flow / Share (TTM)$-1.41
EBITD / Share (Annual)$-19.67
Operating Margin (Annual)-7794.47%
ROI (5Y Avg)-220.19%
EPS Basic Excl Extra (TTM)$-19.31
P/TBV (Quarterly)1.80x
P/B Ratio (Annual)1.17x
Pretax Margin (TTM)-7263.32%
Book Value / Share (Annual)$8.85
Price vs S&P 500 (13W)-51.84%
Beta0.65x
Revenue / Share (TTM)$0.22
ROE (TTM)-411.98%
52-Week Low$0.31
gGradeF
mGradeF
vgmGradeF
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LYRALyra Therapeutics, Inc. Common Stock | — | F | F | $0.70 |
| SYKStryker Corporation | C | C | D | $295.00 |
| MMM3M Company | C | F | C | $151.65 |
| BSXBoston Scientific Corp. | C | B | F | $47.69 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.61 |
| MDLNMedline Inc. Class A common stock | B | D | D | $34.47 |
| DXCMDexCom, Inc. | C | B | C | $72.77 |
| RMDResMed Inc. | B | B | D | $186.46 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.31 |
| SOLVSolventum Corporation | C | D | C | $78.36 |
| PENPenumbra, Inc. | F | C | C | $319.37 |
About
Lyra Therapeutics is a clinical-stage biopharmaceutical company developing innovative drug delivery solutions for ear, nose, and throat (ENT) diseases. The company's lead product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices administered in brief, non-invasive in-office procedures to deliver continuous therapy directly to the sinonasal passages for chronic rhinosinusitis. This localized delivery approach aims to provide therapeutic benefits while minimizing systemic exposure.